- Jan 18, 2001
- 3,499
- 1,177
- 113
- School/Org
- ODwire
- City
- Lansdale
- State
- PA
JACKSONVILLE, FL – (PRNewswire) – Johnson & Johnson (NYSE: JNJ) – October 7, 2025 – Johnson & Johnson, a global leader in eye health, announced new data on the ACUVUE OASYS MAX 1-Day for ASTIGMATISM contact lenses which showed higher end-of-day comfort[III] as compared to Dailies Total1® for Astigmatism. The data will be presented at the American Academy of Optometry’s annual meeting in Boston. Other data being showcased includes ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM extends daily disposable multifocal contact lens options to a new population of presbyopic patients.
“At Johnson & Johnson, our relentless pursuit of innovation drives us to develop solutions that truly transform lives and makes vision possible for more than 40 million people around the world. The ACUVUE OASYS MAX 1-Day family of contact lenses exemplifies our commitment to empowering more patients to see the world with clarity and confidence every day,” said Peter Menziuso, Company Group Chairman, Vision at Johnson & Johnson.[IV]
"New data illustrates the superior advantages of our ACUVUE OASYS MAX 1-Day Contact Lens technology vs. competitive technology. The head-to-head data distinctly highlights the positive impact our lens technology has on patients' vision, reaffirming our leadership in material sciences and contact lens innovation,” said Dr. Caroline Blackie, Vice President of Medical Affairs, Vision, Johnson & Johnson.[II]
New data for ACUVUE OASYS MAX 1-Day for ASTIGMATISM: demonstrating statistical superiority in patient reported outcomes vs. Dailies Total1® for Astigmatism, and the impact of which lens is worn first on subjective performance.
Patient reported vision outcomes for two daily disposable toric soft contact lenses - Giovanna Olivares et al.
###
About Vision at Johnson & Johnson
Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients’ eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at clearvisionforyou.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.
Third party trademarks are the property of their respective owners.
Johnson & Johnson represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
[II] Caroline Blackie is an employee of Johnson & Johnson.
[III] adjusted top 2 box (T2B) scores on a 5-point Likert scale. ACUVUE OASYS MAX 1-Day for ASTIGMATISM contact lenses showed higher (70.4%) end-of-day comfort as compared to Dailies Total1® for Astigmatism (40.6%). T2B is market research method that summarizes survey responses by combining the percentage of respondents who selected the two most positive options on a rating scale.
[IV] Peter Menziuso is an employee of Johnson & Johnson.
References
“At Johnson & Johnson, our relentless pursuit of innovation drives us to develop solutions that truly transform lives and makes vision possible for more than 40 million people around the world. The ACUVUE OASYS MAX 1-Day family of contact lenses exemplifies our commitment to empowering more patients to see the world with clarity and confidence every day,” said Peter Menziuso, Company Group Chairman, Vision at Johnson & Johnson.[IV]
"New data illustrates the superior advantages of our ACUVUE OASYS MAX 1-Day Contact Lens technology vs. competitive technology. The head-to-head data distinctly highlights the positive impact our lens technology has on patients' vision, reaffirming our leadership in material sciences and contact lens innovation,” said Dr. Caroline Blackie, Vice President of Medical Affairs, Vision, Johnson & Johnson.[II]
New data for ACUVUE OASYS MAX 1-Day for ASTIGMATISM: demonstrating statistical superiority in patient reported outcomes vs. Dailies Total1® for Astigmatism, and the impact of which lens is worn first on subjective performance.
Patient reported vision outcomes for two daily disposable toric soft contact lenses - Giovanna Olivares et al.
- This research showed that 62% of patients preferred ACUVUE OASYS MAX 1-Day for ASTIGMATISM for overall vision versus only 18% who preferred Dailies Total1® for Astigmatism.
- Results showed that ACUVUE OASYS MAX 1-Day for ASTIGMATISM was consistently rated higher for overall opinion and all comfort metrics.
- When asked about vision on computer screens and digital device use, 65% preferred the ACUVUE OASYS MAX 1-Day for ASTIGMATISM lens, while only 16% preferred Dailies Total1® for Astigmatism.
- The preference highlights the benefits of the combined innovations of TearStable Technology, OptiBlue Light Filter Technology, and BLINK STABILIZED Design, a design that naturally realigns with every blink and is more independent of gravity, eye gaze and head position1.
- In this research, patients preferred ACUVUE OASYS MAX 1-Day for ASTIGMATISM 3.3x more than Dailies Total1® for Astigmatism.
- When ACUVUE OASYS MAX 1-Day for ASTIGMATISM was worn second, positive feedback of overall opinion increased to 80.0% versus 33.3% for Dailies Total1® for Astigmatism.
- Statistically this is known as an “order effect,” meaning once a patient experiences better performance with a lens, their opinion of a prior lens experience can decrease.
- This study compares the results from two studies, showing that the novel ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM used by a population with 1.00 D to 1.75 D of refractive astigmatism, provides similar vision quality to the ACUVUE OASYS MAX 1-Day MULTIFOCAL for a population with 0.0 D to 0.75 D of refractive astigmatism.
- The new multifocal toric lens therefore extends the coverage by daily disposable multifocal contact lenses to a new population of presbyopic patients.
ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM is the first and only daily disposable contact lens for people with both astigmatism and presbyopia.2 This pioneering contact lens provides patients crisp, clear, stable vision at all distances and in all lighting conditions, along with comfort that lasts all day.3 The lens is now available in the U.S, Canada and select markets in the EMEA and APAC. Additional launches are ongoing.
To learn more about ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM, visit https://www.ACUVUE.com/en-us/oasys-max/.
###
About Vision at Johnson & Johnson
Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients’ eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at clearvisionforyou.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.
Third party trademarks are the property of their respective owners.
Johnson & Johnson represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
[II] Caroline Blackie is an employee of Johnson & Johnson.
[III] adjusted top 2 box (T2B) scores on a 5-point Likert scale. ACUVUE OASYS MAX 1-Day for ASTIGMATISM contact lenses showed higher (70.4%) end-of-day comfort as compared to Dailies Total1® for Astigmatism (40.6%). T2B is market research method that summarizes survey responses by combining the percentage of respondents who selected the two most positive options on a rating scale.
[IV] Peter Menziuso is an employee of Johnson & Johnson.
References
- Data on file 2024, ACUVUE Brand Contact Lenses for ASTIGMATISM overall fitting success, orientation position, rotational stability and vision performance.
- JJV Data on File 2025, World’s First and Only Daily Disposable Multifocal Toric Contact Lens
- JJV Data on file, 2024: Subjective Standalone Claims for ACUVUE OASYS MAX 1-Day MULTIFOCAL Contact Lenses for ASTIGMATISM
